vs
Side-by-side financial comparison of Northfield Bancorp, Inc. (NFBK) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Northfield Bancorp, Inc. is the larger business by last-quarter revenue ($41.3M vs $23.0M, roughly 1.8× Intellia Therapeutics, Inc.). Intellia Therapeutics, Inc. runs the higher net margin — -416.2% vs -1545.5%, a 1129.4% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 12.7%). Northfield Bancorp, Inc. produced more free cash flow last quarter ($52.5M vs $-69.4M). Over the past eight quarters, Northfield Bancorp, Inc.'s revenue compounded faster (15.0% CAGR vs -10.8%).
Northfield Bancorp, Inc. is a regional bank holding company based in the United States, operating primarily across the U.S. Northeast region. It provides a full range of personal and commercial banking services including deposit accounts, mortgage loans, commercial lending, and wealth management solutions for retail consumers, small to medium-sized businesses and local community clients.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
NFBK vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $41.3M | $23.0M |
| Net Profit | $-27.4M | $-95.8M |
| Gross Margin | — | — |
| Operating Margin | -1263.3% | -428.9% |
| Net Margin | -1545.5% | -416.2% |
| Revenue YoY | 12.7% | 78.8% |
| Net Profit YoY | -343.6% | 25.7% |
| EPS (diluted) | $-0.68 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $41.3M | $23.0M | ||
| Q3 25 | $39.2M | $13.8M | ||
| Q2 25 | $38.9M | $14.2M | ||
| Q1 25 | $34.8M | $16.6M | ||
| Q4 24 | $36.7M | $12.9M | ||
| Q3 24 | $31.8M | $9.1M | ||
| Q2 24 | $31.5M | $7.0M | ||
| Q1 24 | $31.3M | $28.9M |
| Q4 25 | $-27.4M | $-95.8M | ||
| Q3 25 | $10.8M | $-101.3M | ||
| Q2 25 | $9.6M | $-101.3M | ||
| Q1 25 | $7.9M | $-114.3M | ||
| Q4 24 | $11.3M | $-128.9M | ||
| Q3 24 | $6.5M | $-135.7M | ||
| Q2 24 | $6.0M | $-147.0M | ||
| Q1 24 | $6.2M | $-107.4M |
| Q4 25 | -1263.3% | -428.9% | ||
| Q3 25 | 37.7% | -808.9% | ||
| Q2 25 | 35.6% | -772.2% | ||
| Q1 25 | 31.0% | -726.6% | ||
| Q4 24 | 38.0% | -1059.9% | ||
| Q3 24 | 27.9% | -1589.0% | ||
| Q2 24 | 29.1% | -1998.6% | ||
| Q1 24 | 27.2% | -394.0% |
| Q4 25 | -1545.5% | -416.2% | ||
| Q3 25 | 27.4% | -735.2% | ||
| Q2 25 | 24.6% | -710.8% | ||
| Q1 25 | 22.6% | -687.6% | ||
| Q4 24 | 30.7% | -1001.2% | ||
| Q3 24 | 20.5% | -1489.5% | ||
| Q2 24 | 18.9% | -2112.6% | ||
| Q1 24 | 19.9% | -371.3% |
| Q4 25 | $-0.68 | $-0.81 | ||
| Q3 25 | $0.27 | $-0.92 | ||
| Q2 25 | $0.24 | $-0.98 | ||
| Q1 25 | $0.19 | $-1.10 | ||
| Q4 24 | $0.27 | $-1.27 | ||
| Q3 24 | $0.16 | $-1.34 | ||
| Q2 24 | $0.14 | $-1.52 | ||
| Q1 24 | $0.15 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $164.0M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $690.1M | $671.4M |
| Total Assets | $5.8B | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $164.0M | $449.9M | ||
| Q3 25 | $131.7M | $511.0M | ||
| Q2 25 | $97.6M | $459.7M | ||
| Q1 25 | $101.7M | $503.7M | ||
| Q4 24 | $167.7M | $601.5M | ||
| Q3 24 | $232.9M | $658.1M | ||
| Q2 24 | $153.5M | $691.1M | ||
| Q1 24 | $238.8M | $791.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $666.4M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $690.1M | $671.4M | ||
| Q3 25 | $719.6M | $748.4M | ||
| Q2 25 | $710.3M | $715.3M | ||
| Q1 25 | $711.1M | $779.9M | ||
| Q4 24 | $704.7M | $872.0M | ||
| Q3 24 | $699.6M | $962.6M | ||
| Q2 24 | $693.0M | $971.1M | ||
| Q1 24 | $698.4M | $1.0B |
| Q4 25 | $5.8B | $842.1M | ||
| Q3 25 | $5.7B | $925.3M | ||
| Q2 25 | $5.7B | $898.9M | ||
| Q1 25 | $5.7B | $986.2M | ||
| Q4 24 | $5.7B | $1.2B | ||
| Q3 24 | $5.7B | $1.2B | ||
| Q2 24 | $5.7B | $1.2B | ||
| Q1 24 | $5.9B | $1.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.95× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $53.7M | $-69.3M |
| Free Cash FlowOCF − Capex | $52.5M | $-69.4M |
| FCF MarginFCF / Revenue | 127.1% | -301.6% |
| Capex IntensityCapex / Revenue | 2.8% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $89.2M | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.7M | $-69.3M | ||
| Q3 25 | $13.9M | $-76.9M | ||
| Q2 25 | $14.1M | $-99.6M | ||
| Q1 25 | $9.4M | $-148.9M | ||
| Q4 24 | $31.1M | $-85.2M | ||
| Q3 24 | $14.0M | $-84.8M | ||
| Q2 24 | $6.9M | $-58.2M | ||
| Q1 24 | $4.2M | $-120.7M |
| Q4 25 | $52.5M | $-69.4M | ||
| Q3 25 | $13.6M | $-76.9M | ||
| Q2 25 | $13.9M | $-99.9M | ||
| Q1 25 | $9.2M | $-149.7M | ||
| Q4 24 | $30.0M | $-86.2M | ||
| Q3 24 | $13.7M | $-86.1M | ||
| Q2 24 | $6.7M | $-59.2M | ||
| Q1 24 | $3.8M | $-123.2M |
| Q4 25 | 127.1% | -301.6% | ||
| Q3 25 | 34.6% | -558.2% | ||
| Q2 25 | 35.7% | -701.0% | ||
| Q1 25 | 26.3% | -900.1% | ||
| Q4 24 | 81.6% | -669.4% | ||
| Q3 24 | 43.2% | -945.2% | ||
| Q2 24 | 21.1% | -850.9% | ||
| Q1 24 | 12.1% | -425.7% |
| Q4 25 | 2.8% | 0.5% | ||
| Q3 25 | 0.8% | 0.2% | ||
| Q2 25 | 0.6% | 1.7% | ||
| Q1 25 | 0.7% | 4.4% | ||
| Q4 24 | 3.1% | 7.6% | ||
| Q3 24 | 0.7% | 14.0% | ||
| Q2 24 | 0.8% | 14.5% | ||
| Q1 24 | 1.4% | 8.7% |
| Q4 25 | — | — | ||
| Q3 25 | 1.29× | — | ||
| Q2 25 | 1.48× | — | ||
| Q1 25 | 1.20× | — | ||
| Q4 24 | 2.76× | — | ||
| Q3 24 | 2.14× | — | ||
| Q2 24 | 1.16× | — | ||
| Q1 24 | 0.68× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NFBK
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
